Navigation Links
Epsen Fuller Group Recruits Operations Leader for Global Biotech Firm SOTIO
Date:4/11/2013

NEW YORK, April 11, 2013 /PRNewswire-iReach/ -- SOTIO a.s, a leader in cell therapy treatments for cancer and autoimmune diseases, has added to their senior leadership team with the addition of Heidi M. Hagen as Chief Operating Officer-US and Head of Global Operations Strategy. As the strategic advisor to SOTIO, Epsen Fuller Group completed the successful placement, which encompassed an exhaustive search of the top operational leaders in biotechnology, and specifically cell manufacturing.

(Photo: http://photos.prnewswire.com/prnh/20130411/CG92806)

"This role is very narrowly focused on cutting-edge therapies based on activated dendritic cells that trigger the immune system for the treatment of cancer and autoimmune diseases", explained Thomas Fuller , Managing Partner of Epsen Fuller Group and leader on his project.

Ms. Hagen is an expert in dendritic cell manufacturing and autologous operations as evidenced in her most recent role as SVP, Operations at Dendreon. Heidi's achievements there were numerous, including building three state-of-the-art, and very high-performing manufacturing facilities, on budget and on schedule. Heidi was formerly at Immunex Corporation, acquired by Amgen, where she held leadership positions in supply chain, clinical operations, and business strategy. Holding an MBA, an MS in Bioengineering, and a BS in cell and molecular biology, all from the University of Washington, Heidi is a widely-recognized authority on cell manufacturing.

"Sotio is focused on becoming a leader in the field of modern biotechnology therapies and related science," says Mr. Fuller. "We were looking for an individual with the real drive and passion to lead the way in commercializing the science of cell manufacturing, thereby enabling SOTIO to flourish as an innovative and fast-growth orga
'/>"/>

SOURCE Epsen Fuller Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Groupe Athena, Inc. Releases 3rd Quarter Financials, Continues Strong Revenue And Earnings Growth
2. Equatorial Guineas [EG] Ministry of Health convenes in Washington, DC with GB Group Global and TNI Biotech (OTCBB:TNIB) to launch major innovative health solutions and improve pharmaceutical quality for its citizens
3. Digital Marketing Groups Growing, Evolving to Respond to Tumultuous Marketing Landscape
4. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
5. Simcere Pharmaceutical Group Announces its Special Committees Engagement of Financial Advisor
6. Chimerixs Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantations Annual Meeting
7. Fortune Magazine Profiles ArcView Group, Co-founded by Steve DeAngelo
8. Bio-pharma Internal Communications Groups Evolving for Structure Optimization
9. Simcere Pharmaceutical Group Announces Issuance of GMP Certificate to Simcere Vaxtec
10. Millennium Research Group Sponsors Case Competition at Western University for Second Year
11. Cellular Biomedicine Group Marks the Launch of China Clinical Trial for TC-DC Therapy for Hepatocellular Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
(Date:7/30/2015)... 2015 Takeda Pharmaceutical Company Limited ("Takeda") ... the post-marketing commitment and submissions of data to ... Bladder Cancer Risk Characterization Study , a large ... in four European countries, for pioglitazone containing medicines, ... years of follow-up. Findings demonstrate that there is ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 2Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 3Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 4Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 5Takeda Announces Completion of the Pioglitazone Post-Marketing Commitment and Submission of Results to the EMA, the FDA and the PMDA 6
... Reportlinker.com announces that a new market ... , Analysis of the Material ... 2009 was one of ... economy, the material test equipment market being ...
... 2012 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... leading China-based exporter and retailer of high-quality medical dressings ... that it will release financial results for its first ... management will host a conference call to discuss these ...
Cached Medicine Technology:Analysis of the Material Testing Equipment Market 2Winner Medical Group Inc. to Host First Quarter 2012 Earnings Conference Call on Thursday, February 9, 2012 at 08:00 p.m. EST 2
(Date:7/31/2015)... ... July 31, 2015 , ... India Network Foundation sponsors visitor health ... or family visit for the past 25 years. As India Network offers coverage for ... travel and spend time with their children and grand children. India Network specializes ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... , ... In an effort to provide the twenty four hour continuous care ... his practice. , The decision will also allow him to spend more time in ... his in-patient admissions to the hospitalists at East Liverpool City Hospital.Dr. Aggarwal has always ...
(Date:7/30/2015)... ... 2015 , ... Eyepartner is proud to highlight that their ... Gaslamp Quarter Plaza for five years this September. , The surveillance and ... any suspicious activity. These cameras are in place to provide inarguable proof in ...
Breaking Medicine News(10 mins):Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 2Health News:India Network Visitor Health Insurance Announces Completion of Food Grains Distribution to Godavari Pushkaram Visitors, Andhra Pradesh, India 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:River Valley Physician Dr. Aggarwal is Making Changes to his Practice 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 2Health News:Eyepartner Software Helps Victims in Gaslamp Quarter Plaza 3
... cerebrovascular disease , MONDAY, Dec. 10 (HealthDay News) -- ... for mild cognitive impairment, says a study by researchers ... City. , Mild cognitive impairment, which causes learning and ... years, particularly as a means of identifying the early ...
... team of researchers from the University of Pennsylvania School ... in the immune system process that fights infection yet, ... tissue., The Penn team, led by Christopher Hunter, chair ... identified the pathways that lead to the production of ...
... Although psychiatrists are among the least religious physicians, they ... and spiritual dimensions of their patients, according to survey ... Journal of Psychiatry. , Ever since Freud described religious ... been tension and at times hostility between religion and ...
... problems with Prilosec and Nexium , , MONDAY, Dec. ... of the popular heartburn drugs Prilosec and Nexium found ... Monday. , The announcement followed a three-month safety review ... preliminary studies. But detailed data from both studies, plus ...
... Dec. 10 JPMorgan,s Annual,Healthcare Conference, which celebrates ... 7-10 at the Westin St. Francis Hotel in ... largest, will feature,presentations from approximately 300 companies, both ... This year,s event will include,panel discussions with leading ...
... mg, * 53% of Patients Treated with 90 mg Dose ... in the Risk of Death ... Compared to Non-responders, ATLANTA, Dec. 10 Pharmion ... data,from the Phase 1/2 study investigating the combined use of MGCD0103, a,novel, ...
Cached Medicine News:Health News:Hypertension Linked to Risk of Mild Cognitive Impairment 2Health News:Researchers led by Penn vet uncover the delicate protein balance behind the immune system response 2Health News:Psychiatrists: Least religious but most interested in patients' religion 2Health News:Psychiatrists: Least religious but most interested in patients' religion 3Health News:Psychiatrists: Least religious but most interested in patients' religion 4Health News:FDA Confirms No Heart Risk From Heartburn Drugs 2Health News:FDA Confirms No Heart Risk From Heartburn Drugs 3Health News:JPMorgan's 26th Annual Healthcare Conference Media Advisory 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7
... DiscoverySE Centrifuges. Workhorse. All in one. ... the new Sorvall Discovery 100SE Ultracentrifuge ... features come with top-of-the-line performance, powerful ... all built into the smallest, quietest, ...
... DiscoveryTMM150 SE Micro-ultra centrifuge continues to raise ... processing, now with 1,048,000 x g performance ... DiscoveryTMM150SE processes sample sizes from 0.2 ... floor footprint, brushless direct drive, very quiet ...
... the highest g-force ever. But optimal productivity ... Optima MAX combines maximum force, capacity, and ... that's worlds apart from any other system. ... enhanced efficiency, Optima takes productivity to the ...
... Efficiency, versatility, and environmental safety ... Optima LE-80 K Ultracentrifuge from ... innovative Optima centrifugation technology, the ... cost effectively provide advanced capability ...
Medicine Products: